Drug Candidate Marketplace
Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. After consenting to the terms of condition and use of our services, the requested information will be provided to you.
|Date||Candidate||Mechanism of action||Indication||Route||Development stage||Note|
|08/07/18||GEM033||Inhibitors of bacterial resistance mechanisms||Gram-negative MDR bacterial infections, lung infections in cystic fibrosis （CF） patients||see Note||Preclinical||Restore effectiveness of shelved antibiotics.
Lower the effective dose of antibiotics.
Mitigate antibiotic resistance.
Disrupt biofilm-based infections.
Over 1,000 compounds with lead compounds for each indication identified.
Route : Intravenous, Aerosol, Topical
|07/26/18||GEM032||Calcium release-activated calcium channel inhibitor||Respiratory & immuno-inflammatory diseases||Oral||Phase 1||- Preclinical study demonstrated the therapeutic potential in respiratory diseases causally associated with allergic inflamation.
- Phase 1 SAD/MAD study were completed.
|07/26/18||GEM031||Calcium release-activated calcium channel inhibitor||Lymphomas & Solid cancer||Oral||Phase 1||- Demonstrated preclinical activity in a broad range of cancers.
- Phase 1 dose-escalation study in patients with relapsed or refractory lymphomas is ongoing.
|07/26/18||GEM030||PI3K δ/γ dual inhibitor||Hematological malignancies, T cell Lymphoma, Hodgkin Lymphoma||Oral||Phase 2||- Highly specific dual PI3K δ/γ inhibitor with nano‐molar inhibitory potency
- Single-agent and combination with immune checkpoint inhibitor programs
- Inhibits primary patient leukemic/lymphoma cells
- Dose escalation study demonstrated an acceptable safety and tolerability with promising clinical activity
|07/20/18||GEM029||A cancer stem cell-associated transcription factor inhibitor||Malignant gliomas including glioblastoma （GBM）||Oral||Phase 1 ready||-Directly kills the cancer stem cells.
-Significantly improves survival in orthotopic GBM PDX models.
-Inhibits tumor growth in a mouse implanted with GBM cells and the growth inhibition is augmented by combination with temozolomide/radiation.
-No significant toxicities are identified at therapeutic doses.
|07/09/18||GEM028||miRNA targeting refractory colon cancer with mutated K-ras and refractory pancreatic cancer||pancreatic cancer colon cancer||IV||Preclinical||The miRNA regulates K-ras, Bcl2, survivin, and NF-kB and demonstrate excellent antitumor effect in vitro and in vivo.||Contact|
|07/09/18||GEM027||miRNA targeting refractory colon cancer with mutated K-ras||colon cancer||IV||Preclinical||The miRNA regulates EGFR signaling pathway by directly inhibiting of both KRAS and AKT1 and demonstrate excellent antitumor effect in vitro and in vivo.||Contact|
|07/09/18||GEM026||siRNA suppressing the expression of novel cancer stem cell gene "Gene A"||Cancer||IV||Preclinical||-Novel cancer stem cell gene "Gene A", which was discovered by single cell analysis of cancer stem cell, shows character as follows.
1.Superior cancer stem cell diagnostic marker than known cancer stem cell marker CD44v9
2.SiRNA targeting Gene A demonstrate excellent antitumor effect with currnet medicines.
|07/09/18||GEM025||miRNA suppressing the expression of a protein characteristic of pancreatic cancer stem cells||pancreatic cancer||IV||Preclinical||Excellent antitumor effect was demonstrated in uniquely established pancreatic cancer stem cell model in vitro and in vivo.||Contact|
|07/09/18||GEM024||Selective inducer of apoptosis through modulation of NF-kB||Oral Squamous Cell Carcinoma||Phase 2 ready （FDA approved IND）||-First-in-class, combination therapeutic that simultaneously upregulates a cluster of genes promoting cell death and downregulates a cluster of genes promoting survival of cancer cells.
-Phase 1 in USA results showed no significant AE and dose-dependent modulation of key biomarkers involved in disease pathogenesis.
Route : Oral, pastille based topical delivery